Dyadic FY2024: revenue $3.5M (+21%), net loss $5.8M ($0.20/shr), cash $9.3M

DYADIC INTERNATIONAL INC

Revenue $3.495M, up from $2.899M in 2023; driven by $1M Proliant license and $890k Inzymes success fees.
Net loss $5.809M ($0.20 per share), improved from $6.795M ($0.24 per share) in 2023.
Cash and investment-grade securities $9.288M at Dec 31, 2024 vs $7.273M at year-end 2023.
Up to $7.5M in grants from CEPI (up to $2.4M for Dyadic) and Gates Foundation for C1 platform.
Human Serum Albumin commercial launch expected Q2 2025; DNase1 advancing with EU CDMO partnership.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.